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Abstract: Bacterial biofilm is a major factor in delayed wound healing and high levels of biofilm
production have been repeatedly described in multidrug resistant organisms (MDROs). Nevertheless,
a quantitative correlation between biofilm production and the profile of antimicrobial drug resistance
in delayed wound healing remains to be determined. Microbial identification, antibiotic susceptibility
and biofilm production were assessed in 135 clinical isolates from 87 patients. Gram-negative
bacteria were the most represented microorganisms (60.8%) with MDROs accounting for 31.8% of
the total isolates. Assessment of biofilm production revealed that 80% of the strains were able to
form biofilm. A comparable level of biofilm production was found with both MDRO and not-MDRO
with no significant differences between groups. All the methicillin-resistant Staphylococcus aureus
(MRSA) and 80% of Pseudomonas aeruginosa MDR strains were found as moderate/high biofilm
producers. Conversely, less than 17% of Klebsiella pneumoniae extended-spectrum beta-lactamase
(ESBL), Escherichia coli-ESBL and Acinetobacter baumannii were moderate/high biofilm producers.
Notably, those strains classified as non-biofilm producers, were always associated with biofilm
producer bacteria in polymicrobial colonization. This study shows that biofilm producers were
present in all chronic skin ulcers, suggesting that biofilm represents a key virulence determinant
in promoting bacterial persistence and chronicity of ulcerative lesions independently from the
MDRO phenotype.
Keywords: skin ulcer; MDRO; biofilm; wound; MRSA; ESBL; Pseudomonas aeruginosa;
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1. Introduction
Wounds are particularly predisposed to microbial colonization and considered at very high
risk for multidrug resistant organism (MDRO) infections [1–5]. Clinical/surgical management of
chronic wounds accounts for 2–4% of the total health budget in western countries and this estimate is
expected to increase due to population aging and to the growing number of people with predisposing
factors such as diabetes and obesity [6,7]. Generally, the most common MDROs isolated from
patients with chronic ulcerations include methicillin-resistant S. aureus (MRSA), bacteria producing
extended-spectrum beta-lactamase (ESBL) and carbapenemases (K. pneumoniae and E. coli), as well
as multidrug resistant P. aeruginosa (MDRPA) and A. baumannii [8]. Nevertheless, the prevalence of
MDROs can significantly differ either temporally or geographically, also depending on the specific
healthcare setting [4,8–11]. Consequently, the approaches to prevent and control MDROs should be
tailored to the specific needs of each population and institution. Patients with chronic ulcers usually
harbor a variety of colonizing bacterial species [12]. An accurate microbiological diagnosis is essential
to prevent serious infections and to avoid inappropriate treatment that causes deterioration of the
wound, thus delaying healing. Considering that initial treatment is empirical in about two-thirds of
the cases, selecting an appropriate empiric antibiotic regimen is critical and requires knowing the usual
etiologic organisms and the local prevalence of pathogens, especially antibiotic-resistant strains [13,14].
Complications related to non-healing ulcers are not limited to the presence of MDRO. In fact,
increasing evidence suggests that biofilm may represent a major virulence factor in the pathogenesis
of chronic ulceration [15–17]. The term “critical colonization” defines a condition in which the host
defenses are compromised and bacteria induce the failure of wounds healing in the absence of signs of
systemic infection [18,19]. Thus, “critical colonization” is the clinical condition that better identifies
the putative role of bacterial biofilm in a chronic wound [20]. Indeed, chronic ulcers offer an ideal
environment for biofilm formation due to the reduced host immune response in the wounded area,
characterized by the presence of necrotic tissue that, in turn, can promote microbial adhesion [10,21].
This is confirmed by electron microscopy of biopsies revealing that biofilm is present in almost 60%
of the samples from chronic wounds in comparison with only 6% of biopsies deriving from patients
with acute wounds [22]. On the other hand, bacteria endowed in a mature biofilm matrix, firmly
adherent to the surrounding tissues, can effectively escape the host local immune response as well as
the conventional antimicrobial treatments. As a result, they are particularly difficult to eradicate since
they require a minimum inhibitory concentration (MIC) impossible to reach in vivo, due to the side
effects and the toxicity of the drugs at renal and/or hepatic level [23–25].
Although several reports described a higher level of biofilm production by MDROs, the correlation
between biofilm production and the acquisition of antibiotic resistance is still debated [26–29].
Numerous studies to date highlight the importance of the bacterial biofilm as a potential virulence
factor contributing to microbial invasiveness and persistence. However, biofilm production is not
routinely investigated in clinical microbiology testing. In fact, conventional clinical microbiology
testing targets only the planktonic microbial forms, which are entirely different from the sessile
forms, endowed within the biomass [30–32]. Thus, assessment of the biofilm production capabilities
represents a necessary prerequisite for the development of novel medical or surgical therapeutic
interventions, since, at present, the most effective strategy against biofilm consists of its surgical
removal from the wound surface [33].
This study aimed at investigating the spectrum of microbial colonization in patients with chronic
ulcers and at evaluating the biofilm production capabilities of drug resistant Gram-positive and
Gram-negative bacteria.
2. Results
From the 87 patients with a colonized skin ulcer included in the study, 52% percent were men and
48% women, with a mean age of 62 years (standard deviation 16.73, range 23–94). The most relevant
pathologies reported were venous leg ulcers in 56.3% of cases, with diabetic ulcerations involved in
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18% of cases and pressure ulcer accounting for 25.2%. Other entities included ulcerations secondary to
a trauma (7.8%) and neoplasms (5.8%) and arterial leg ulcers described in 4.9% of patients. A total
of 135 different bacterial species were isolated from ulcerations. In particular, single bacterial species
were isolated from 45 ulcerative lesions, while two different species were observed in 36 lesions. In the
remaining six cases, the presence of three different microorganisms was observed.
Globally, sixteen different pathogenic bacterial species were identified. Specifically, Gram-negative
bacilli were more frequently (66.7%) isolated from the ulcer swabs than Gram-positive cocci (33.3%).
Nevertheless, the Gram-positive S. aureus was the most common pathogen isolated, accounting for
27.4% of the total microorganisms (Figure 1). Among the Gram-negative bacteria, the most frequent
species was P. aeruginosa (14.1%).
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morganii, Streptococcus agalactiae, Klebsiella oxytoca, Enterobacter aerogenes, Proteus vulgaris and Serratia 
marcescens. Data in percentage. In brackets, the absolute occurrence of different bacterial species. Blue 
= Gram-positive; red = Gram-negative. 
In descending order, other species isolated were Proteus mirabilis (11.9%), E. coli (11.1 %),  
A. baumannii (8.9%) and K. pneumoniae (7.4%), respectively. Moreover, S. aureus, P. aeruginosa,  
P. mirabilis and K. pneumoniae were the microorganisms most frequently found with other bacteria in 
polymicrobial associations. The most common polymicrobial association was between S. aureus and 
P. aeruginosa, which was observed in 10 cases. 
2.1. Microbial Drug-Resistance Profiles 
Of the total of 135 isolates, 92 (68.2%) were antibiotic-sensitive isolates (Not-MDRO) and 43 
(31.8%) were classified as MDROs. The antibiotic susceptibility patterns of not-MDRO isolates are 
summarized in Tables 1 and 2, respectively. Methicillin-sensitive S. aureus (MSSA) were 70% to 100% 
responsive to all tested antibiotics, showing a 69.6% resistance only to benzylpenicillin.  
P. aeruginosa was totally susceptible to amikacin, ceftazidime, imipenem and meropenem, while, in 
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responsive to all tested antibiotics, showing a 69.6% resistance only to benzylpenicillin. P. aeruginosa
was totally susceptible to amikacin, ceftazidime, imipenem and meropenem, while, in 14.3% of
cases, it showed resistance to ciprofloxacin and gentamicin. K. pneumoniae had a 50% resistance to
gentamicin, the 3rd and 4th generation cephalosporins, amoxicillin/clavulanic acid, carbapenems
and piperacillin/tazobactam, while amikacin was the only effective antimicrobial agent against this
species. Carbapenem, aminoglycoside, the 3rd and 4th generation cephalosporins and nitrofurantoin
had the same activity against E. coli; in fact, 100% of the bacterial species was susceptible to these
agents. P. mirabilis showed high resistance to the antimicrobial agents tested; it was 100% sensitive
only to ertapenem and meropenem. Tables 1 and 2 summarize the profile of antibiotic resistance of all
the other Gram-negative bacilli and Gram-positive cocci, respectively.
Table 1. Antibiotic resistance pattern of Gram-negative bacilli not MDR (% of resistance). n represents
the number of samples. Blank: data not available.
Drug E. colin = 9
K. pneumoniae
n = 4
P. mirabilis
n = 16
E. cloacae
n = 5
C. freundii
n = 2
M. morganii
n = 2
P. aeruginosa
n = 14
Amikacin 0 0 43.8 0 0 0 0
Gentamicin 0 0 75 0 0 50 14.3
Tobramycin 50 11.1
Ertapenem 0 0 0 0
Imipenem 0 0 0 0 0
Meropenem 0 0 0 0 0 0
Cefepime 0 0 25 0 0 0 7.1
Cefotaxime 0 0 62.5 0 0 100
Ceftazidime 0 0 62.5 0 0 100 0
Nitrofurantoin 0 100
Amoxicillin/clavulanic acid 22.2 0 100 100 100
Piperacillin/Tazobactam 0 0 0
Colistin 0 0 100 0 100 7.1
Ciprofloxacin 22.2 0 68.8 0 0 66.6 14.3
Levofloxacin 50
Trimethoprim/sulfamethoxazole 55.5 0 75 20 0 50 100
Tigecycline 100 100
Table 2. Antibiotic resistance pattern of Gram-positive cocci not MDR (% of resistance).
MSSA = methicillin-sensitive S. aureus. n represents the number of samples. Blank: data not available.
Drug MSSAn = 23
E. faecalis
n = 6
S. agalactiae
n = 2
Gentamicin 18.2
Gentamicin High Level Resistance 40
Streptomycin High Level Resistance 80
Imipenem 0
Teicoplanin 4.3 0 0
Vancomycin 0 0 0
Clindamycin 26.1 100 100
Daptomycin 0
Erythromycin 31.8 66.7
Nitrofurantoin 0 0
Linezolid 0 0 0
Ampicillin/sulbactam 0
Benzylpenicillin 69.6 0
Oxacillin 0
Levofloxacin 8.7 50 0
Moxifloxacin 0
Trimethoprim/sulfamethoxazole 0 100 0
Tetracyclin 8.7 100
Fusidic Acid 0
Tigecycline 0 0 0
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The assessment of MDROs (Figure 2) revealed that, within the 37 isolates of S. aureus, 14 (37.8%)
were MRSA and 23 methicillin-sensitive S. aureus (MSSA). In particular, MRSA could be identified in
10.4% of the totality of the microorganisms.Int. J. Mol. Sci. 2017, 18, 1077 5 of 18 
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Figure 2. Quantity of not-MDRO (red) compared to its respective counterparts MDRO (blue): MRSA
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K. pneumoniae, respectively, and A. baumannii.
Of the 19 P. aeruginosa isolates, five were MDRPA representing 26.3% of the P. aeruginosa
isolates and 3.7% of the microorganisms analyzed. Among the 15 isolates of E. coli, six (40%) were
ESBL-producers accounting for 4.4% of all microorganisms isolated in the ulcerations. A. baumannii
was isolated from 12 samples (8.9%) and, in all cases, was classified as MDRO. Regarding the
10 K. pneumoniae isolates, six (60%) were ESBL-producers, resulting in 4.4% of all the identified
microorganisms. As expected, MRSA were 100% resistant to benzylpenicillin and oxacillin. Conversely,
they were sensitive (100%) to tigecycline, linezolid and vancomycin, while more than 40% were resistant
to clindamycin, 50% resistant to erythromycin and gentamicin and 64.3% resistant to levofloxacin,
respectively. Of note, we have observed the presence of three S. aureus strains (1 MSSA and 2 MRSA)
identified as vancomycin resistant. In those cases, the vancomycin susceptibility profile was further
verified by the minimal inhibitory concentration methods as suggested by the EUCAST clinical
breakpoint tables. This latter testing revealed that all the S. aureus strains, previously identified
as vancomycin resistant by the automated antimicrobial susceptibility assessment, were, in fact,
vancomycin susceptible, scoring a minimum inhibitory concentration (MIC) < 1 µg/mL. These results
support previous reports pointing to the risk of significant discordances in vancomycin resistance
profiling as assessed by different susceptibility tests [34].
Table 3 illustrates the drug resistance profiles of all MDROs. MDRPA showed between 80%
and 100% of resistance to amikacin, cefepime, ciprofloxacin, gentamicin and tobramycin. Moreover,
it was resistant (from 20% to 40%) to carbapenems (meropenem and imipenem) and, in 60% of
the cases, to ceftazidime, being sensitive only to colistin. A. baumannii showed 100% resistance to
amoxicillin-clavulanic acid, the 3rd and 4th generation cephalosporins and fosfomycin. More than
70% resistance was noted to gentamicin, imipenem, trimethoprim-sulfamethoxazole and ciprofloxacin
being susceptible only to colistin.
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Table 3. Antibiotic resistance pattern of MDROs (% of resistance). Blank: data not available.
MRSA = methicillin-resistant; ESBL = positive to the production of extended-spectrum beta-lactamase;
MDRPA = multidrug resistant P. aeruginosa. n represents the number of samples.
Drug MRSAn = 14
A. baumannii
n = 12
E. coli ESBL
n = 6
K. pneumoniae ESBL
n = 6
MDRPA
n = 5
Amikacin 16.7 33.3 80
Gentamicin 50 75 100 66.7 100
Tobramycin 100
Ertapenem 0
Imipenem 75 0 33.3 20
Meropenem 0 33.3 40
Cefepime 100 100 100 80
Cefotaxime 100 100 100
Ceftazidime 100 100 100 60
Teicoplanin 7.1
Vancomycin 0
Clindamycin 42.9
Daptomycin 7.7
Erythromycin 50
Nitrofurantoin 0
Linezolid 0
Amoxicillin/clavulanic acid 100 33.3 83.3 100
Benzylpenicillin 100
Oxacillin 100
Piperacillin/Tazobactam 20 83.3
Colistin 0 0 50 0
Ciprofloxacin 91 100 83.3 80
Levofloxacin 64.3
Moxifloxacin 15.4
Trimethoprim/sulfamethoxazole 14.3 75 66.7 83.3 100
Tetracyclin 28.8
Fosfomycin 100 0 66.7
Fusidic Acid 7.1
Both ESBL-producing E. coli and K. pneumoniae showed 100% resistance to the 3rd and 4th
generation cephalosporins. Moreover, ESBL-producing E. coli was resistant (100%) to gentamicin and
ciprofloxacin and sensitive (100%) to carbapenems, colistin, fosfomycin, nitrofurantoin and tigecycline,
respectively. ESBL-producing K. pneumoniae showed a high resistance (83.3%) to amoxicillin-clavulanic
acid, ciprofloxacin, piperacillin-tazobactam and trimethoprim-sulfamethoxazole, and, in addition, it
was also resistant (50%) to colistin.
2.2. Assessment of Microbial Biofilm Production
The ability to produce biofilm was evaluated in all 135 bacterial isolates, including both MDRO
and not-MDRO species, using the clinical BioFilm Ring Test (cBRT) [35]. Results showed that 79.3% of
the isolates were able to produce biofilm (Figure 3A). Of the 43 MDROs analyzed, the biofilm-producing
strains accounted for 74%, whereas, among the 92 not-MDROs analyzed, 86% were capable of forming
biofilm (Figure 3B). Comparable profiles of biofilm production were observed in both MDRO and
not-MDRO species (Figure 3B) and the statistical analysis revealed no significant differences between
groups (p = 0.94).
Moreover, the biofilm profiling at the level of single bacterial species revealed that 94.6% of
S. aureus isolates and 73.7% of the P. aeruginosa strains were moderate/high biofilm producers,
respectively (Figure 3C). Conversely, only 60.0% of K. pneumoniae ESBL strains were found to produce
biofilm and none of them was a high biofilm producer. Among the 12 A. baumannii strains, 58.3% were
found to produce biofilm. Finally, E. coli was found to be the weakest biofilm producer with only 53.3%
of the strains capable of forming biofilm (Figure 3C). Globally, S. aureus and P. aeruginosa showed a
comparable ability to form biofilm (p = 0.1) and this ability was significantly higher with respect to
K. pneumoniae, E. coli and A. baumannii (p < 0.05), respectively (Figure 3C).
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Figure 3. Biofilm production of bacterial isolates from patients with chronic skin ulcers. (A) biofilm
production of the total bacterial isolates; (B) of MDRO and not-MDRO; (C) of the different bacterial
species and according to multidrug resistance profile: (D) MRSA (n = 14) vs. MSSA (n = 23); (E) MDRPA
(n = 5) vs. P. aeruginosa (n = 14); (F) K. pneumoniae ESBL (n = 6) vs. K. pneumoniae (n = 4), E. coli ESBL
(n = 6) vs. E. coli (n = 9), and A. baumannii (n = 12) compared with the rest of isolates (n = 42). Biofilm
formation was assessed by the cBRT and clinical isolates were classified as non-producers, weak,
moderate and high biofilm producers. All results expressed as percentage of strains with the specific
biofilm-forming ability.
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Comparative analysis performed to evaluate different abilities to produce biofilm of the MRSA
and not-MRSA, at the level of single bacterial species (Figure 3D–H), showed no significant differences
between groups (p > 0.05). Of note, the vast majority of the bacterial isolates, present as single colonizers,
were moderate/high biofilm producers. In particular, from the 45 ulcerative lesions colonized by
single bacterial species, weak biofilm producers were found only in six cases (13.3%), while in the
remaining 41 cases (86.6%), colonization was sustained by moderate/high biofilm-producers. Notably,
all the strains, either belonging to MDRO or not-MDRO groups, identified as biofilm non-producers,
were always associated in polymicrobial colonization with moderate/high biofilm producer strains.
3. Discussion
Data from this study show that Gram-negative bacteria were the most common colonizing species
in chronic ulcerations, accounting for up to 60.8% of the isolates, and that MDROs accounted for
the 31.8% of the total microbial isolates. Nevertheless, considering the individual bacterial species,
S. aureus was the most common pathogen, found in 27.4% of the lesions. These data are consistent
with previous studies describing a rate of colonization between 10% and 40%, with approximately
20% of the human population permanently colonized in their noses and another 60% of individuals
considered intermittent carriers [36–41]. Higher carrier rates, however, were described in hospitalized
patients or in patients with atopic dermatitis [40,41]. Among the 37 isolates of S. aureus, 14 were MRSA
(37%), representing 10.3% of all microorganisms isolated. This suggests a higher frequency of MRSA,
with respect to all S. aureus isolation in our hospital, as compared with previous studies [37]. In fact, to
limit the spread of S. aureus, it has been recently activated in our institution a novel screening protocol
for nasal MRSA detection, since S. aureus nasal carriage is a recognized risk for either nosocomial or
community-acquired infections as well as presenting a high risk for ulcer colonization [42–44].
Apart from benzylpenicillin, clindamycin, erythromycin, MSSA showed a sensitive profile with
80% to 100% of the antibiotics tested. Conversely, MRSA showed high levels of antimicrobial resistance
and the most effective agents were found to be linezolid and tigecyclin.
In addition, we found an apparent gender-specific preference in ulcers colonization by S. aureus.
In fact, of the 37 S. aureus isolated, 24 originated from male patients and only 13 from female patients.
This result is in contrast with other studies that reported a preferential colonization of S. aureus in
females, and further suggests reconsidering possible differential gender-specific habits such as body
hygiene [45]. Although S. aureus was the most prevalent individual microbial species, Gram-negative
bacteria were the most abundant (60.8%) colonizing pathogens. Among them, P. aeruginosa was
the second-most prevalent species, accounting for up to 14.1% of all microbial isolates. Many
studies showed a large variation in the incidence of P. aeruginosa in ulcers, spanning from 14.6% to
34.1% [37,38,46]. One explanation for this high variability can be ascribed to the polymicrobial nature
of wound communities and to the fact that P. aeruginosa preferentially localizes deeper in the wound
tissue, thus resulting in being more difficult to isolate [47,48]. Despite P. aeruginosa is considered an
easy-to-culture bacterium, in several cases of culture failure, molecular based techniques were effective
at detecting this microorganism [49]. Thus, the isolation of P. aeruginosa by traditional culturing might
be somehow limited, further raising the issue on the effectiveness of swabs for the detection of this
bacterium. In this study, P. aeruginosa was detected in 14 cases of multiple colonizations, and, in 10 of
these events, it was found to be associated with S. aureus.
Differently from P. aeruginosa isolates, MDRPA showed a much higher resistance to
aminoglycosides (amikacin, gentamicin, tobramycin), cephalosporins and ciprofloxacin, and displayed
a 20% to 40% resistance to carbapenems, being 100% sensitive only to colistin.
The other Gram-negative bacteria isolated include P. mirabilis (11.9%), E. coli (11.1%), A. baumannii
(8.9%) and K. pneumoniae (7.4%). We noted that a considerable percentage of these species showed
high resistance to the antibiotics tested. In particular, 100%, 60%, 40% and 26.3% of A. baumannii,
K. pneumoniae, E. coli and P. aeruginosa, respectively, had an MDRO phenotype. ESBL-producing E. coli
showed a 100% resistance to the 3rd generation (cefotaxime, ceftazidime) and the 4th generation
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(cefepime) cephalosporins, to ciprofloxacin and to gentamicin, but it was highly susceptible (70–100%)
to all other antibiotics tested (with the exception of trimethoprim/sulfamethoxazole). ESBL-producing
K. pneumoniae was resistant (100%) to the 3rd and 4th generation cephalosporins, and showed
also 83.3% resistance to amoxicillin/clavulanic acid, ciprofloxacin, piperacillin/tazobactam and
trimethoprim/sulfamethoxazole. Carbapenem and amikacin were the only effective antimicrobial
agents against this organism. Colistin represented the only effective drug against A. baumannii, which
is the species that showed the highest resistance to the panel of antibiotics tested, as compared with all
other MDROs.
Although usually classified as non-MDRO, P. mirabilis and M. morganii showed a high level of
beta-lactams resistance, an aspect which is rarely taken into consideration [50]. P. mirabilis is generally
susceptible to β-lactams, due to the lack of a chromosomally encoded AmpC cephalosporinase.
However, sporadic acquisition of different types of β-lactamases through plasmid-mediated
mechanisms has been reported [51–53]. The individuals included in this study were all chronically
colonized by different bacteria (including MDRO and non-MDRO), growing within a biofilm matrix
and exposed to repeated antimicrobial treatments. Thus, it is tempting to speculate that such
biofilm-endowed, polymicrobial colonization may have provided a most favorable environment
for the exchange of plasmid-mediated antimicrobial resistance. On the other hand, M. morganii is
also not generally classified as ESBL. Nevertheless, it has a known capability to express an inducible,
chromosomally encoded, AmpC beta-lactamase with a high catalytic activity on classical penicillins,
cefoxitin, narrow-spectrum cephalosporins, and cefotaxime, a property, which is consistent with the
susceptibility profile presented in Table 1 [54].
It has been reported that biofilm production, particularly by MDROs, may play a relevant role
in the pathogenesis of chronic wounds, considering its effects on the antibiotic resistance and the
ensuing limitation of therapeutic options [16,22]. In the present study, we have found a strong
propensity at biofilm formation by most microbial isolates. In fact, we found that up to 80.5% of the
microbial strains analyzed were able to produce biofilm. These data are in accordance with previous
reports, which described percentages of biofilm-producing bacteria between 60% and 90% in chronic
wounds [22,47,49,55,56]. In particular, of the 135 strains analyzed 27.5% were classified as high, 26%
as moderate, and 29.2% as weak biofilm producers, respectively. However, we found a comparable
ability to produce biofilm in both MDRO (74.4%) and Not-MDRO (78.9%) strains, with no significant
differences between the two groups (p = 0.94).
The role of biofilm in facilitating the emergence of resistance to antibacterial agents is still debated.
However, it is largely recognized that a mature biofilm matrix may allow bacteria to elude the
host immune response while forming a barrier against most conventional antimicrobial treatments.
In addition, other biofilm-related mechanisms of drug resistance should be considered. For instance,
the horizontal gene transfer is increased in biofilm growing bacteria in vitro, and this process is
considered to be responsible for the acquisition of antibiotic resistance in vivo, both at single species
and multispecies levels [57–59]. Enhanced rates of conjugation have been also reported in the biofilm
of enterococci and Pseudomonas spp. [60,61]. Increased mutation frequencies have been described
in biofilm cultures of P. aeruginosa, S. aureus, Staphylococcus epidermidis and Streptococcus pneumoniae,
suggesting that the biofilm matrix provide a favorable environment to promote mutational resistance
to antibiotics [62–64]. Moreover, bacterial biofilm appears to promote the maintenance of plasmids
in the regions dominated by persister cells, that is, the residual bacteria present in the biofilm matrix
as a dormant or non-growing microbial fraction, which is excluded by processes of competition
and therefore able to preserve episomal factors [65]. On the other hand, it has been suggested that
the slow diffusion of antibiotic drugs within the biofilm matrix might sustain the development of
multidrug resistance, possibly by selecting highly tolerant strains transiently exposed to sub-inhibitory
concentrations of antimicrobial drugs [59,66,67]. Nevertheless, some experimental evidence indicates
that fluoroquinolones, tetracycline, rifampin, daptomycin and vancomycin can rapidly diffuse into the
deeper levels of biofilm [68–74].
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In this study, all of the 37 S. aureus isolates, including both MRSA and MSSA, showed a high level
of biofilm production with no significant differences in the level of biofilm formation between groups
(p = 0.10). This result is in accordance with previous reports, which failed to find any association
between methicillin resistance and an increased ability to produce biofilms [26,29,75–78]. Nevertheless,
other authors described a significantly higher rate of biofilm formation in S. aureus strains with
greater multidrug resistance as compared with more susceptible strains [27]. Specifically, MRSA
isolates were found to display higher adhesion properties than MSSA strains on bronchial epithelial
cells and the expression of functional penicillin binding protein 2a (PBP2a), which is responsible
for methicillin resistance, correlated with increased catheter adhesion ability [79,80]. In S. aureus,
the acquisition of methicillin resistance has pleiotropic effects by reducing toxin production, altering
biofilm formation and eventually reducing virulence [79]. The large number of results, often conflicting,
on the adherence ability of the MRSA and MSSA strains may be associated with different strategies
adopted by S. aureus in response to the environment, according to various sites of isolation. In health
care-associated infections, MRSA has been found to exert an attenuated virulence with respect to
community-associated infections by MRSA (CA-MRSA) strains [81]. This difference may reflect an
adaptation to healthcare settings and to more vulnerable patients, whereas the equilibrium between
antibiotic resistance and virulence observed in CA-MRSA appears more consistent with the need to
infect healthy individuals [79,81]. Our results are representative of a specific court of patients where
chronic ulcers more likely offer a selective advantage and an ideal environment for biofilm-producing
S. aureus, independently from the acquisition of multidrug resistance.
Biofilm is considered an important virulence factor in several cases of infection/colonization
by P. aeruginosa [82]. This is also confirmed by our study revealing that 100% of the MDRPA strains
and 92.9% of the more susceptible P. aeruginosa isolates were able to produce biofilm. Comparison of
biofilm production amongst P. aeruginosa clinical isolates showed no association between the multidrug
resistance phenotype and the ability to produce biofilm (p = 0.87). Nevertheless, in previous reports,
dealing with a larger number of P. aeruginosa, propensity to form biofilm was found significantly
higher in MDRPA as compared to susceptible isolates deriving from infected wounds and from
contaminated contact lens [29,83,84]. Here, we found that S. aureus (p < 0.01) and P. aeruginosa (p = 0.02)
were frequently found in association, and this result is consistent with previous studies reporting
that the dual infection causes a more severe patient outcome than an infection sustained by a single
microorganism [5,37,42,47,85–87]. Generally, the dual infection S. aureus/P. aeruginosa causes the
worsening of the outcome in patients with chronic wounds than single infections [85,86,88]. The
interactions between P. aeruginosa and S. aureus, studied in an “in wound-like” model, demonstrated
that P. aeruginosa and S. aureus tend to coexist stably and that this association provides a mutual benefit
in terms of increased antibiotic tolerance [87].
Second only to P. aeruginosa among the nosocomial, aerobic, nonfermentative, Gram-negative
bacilli, A. baumannii can harbour and transfer diverse antibiotic resistance determinants [89].
A. baumannii is recognized as an important multidrug resistant pathogen causing a major threat for
hospitalized patients and biofilm is repeatedly implicated as an important determinant of virulence [28].
In our study, 58.3% of the A. baumannii were able to produce biofilm, a significantly low percentage
compared with those observed for S. aureus and P. aeruginosa but in accordance with previous studies
showing that 50–63% of the A. baumannii isolates were able to form biofilm [28,90,91]. Interestingly,
five out of 12 strains of A. baumannii were classified as non-biofilm producers and those strains were
always associated in multiple colonizations with biofilm-producing isolates. In addition, only a small
number of A. baumannii isolates (16.3%) were classified as moderate/strong biofilm producers. These
results suggest that, for A. baumannii, antibiotic resistance is key for the successful colonization of
patients with chronic ulcers and that biofilm-producing polymicrobial colonization may increase the
environmental resilience. Thus, it remains an open question whether A. baumannii biofilm production
and the acquisition of multiple resistances coexist under the same selective pressure driven by the
hospital environment. It has been reported that the acquisition of the MDR phenotype in A. baumannii
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occurs at the expense of biofilm formation, whereas, in the non-MDR isolates, biofilm production
has a more important role in the bacterial persistence [92]. On the other hand, several authors
dispute the existence of a possible relationship between biofilm formation and MDR phenotype in
A. baumannii, based on the notion that weak biofilm producers often display a high level of multidrug
resistance [92,93]. Consistent with these observations, high biofilm-producing A. baumannii was found
to be sensitive to several antibiotics, suggesting that biofilm may not be necessary for a successful
dissemination of A. baumannii within the hospital setting [94].
Likewise, considering K. pneumoniae, the percentage of biofilm producers was significantly lower
than that of S. aureus and P. aeruginosa (p < 0.05). Specifically, 66.7% and 50% of K. pneumoniae-ESBL
and K. pneumoniae, respectively, were able to form biofilm with no significant differences in the overall
level of biofilm production (p = 0.93). Additionally, none of the K. pneumoniae-ESBL and K. pneumoniae
isolates were found to be strong biofilm producers and all the isolates were detected in polymicrobial
colonizations. Previous in vitro studies revealed that approximately 40–50% of K. pneumoniae clinical
isolates, derived from different materials, were able to form biofilm [34,95]. The existence of a
significant correlation between antibiotic resistance and the level of biofilm production has been
reported in K. pneumoniae isolates deriving from sputum and urine, but limited data are available from
strains isolated from wounds [96]. E. coli, irrespective from the multidrug resistance phenotype, was
classified as the weakest biofilm producer. The percentage of strains able to form biofilm was 33.3%
and 66.7% for E. coli-ESBL and E. coli, respectively. Despite the level of biofilm producers being higher
within the E. coli isolates as compared with their multidrug resistant counterpart, the difference was
not statistically significant (p = 0.63), possibly due to the limited number of strains.
It is important to highlight that those bacterial strains classified as non-biofilm producers were
always found to be in association in polymicrobial colonization with biofilm producer strains. Isolation
of multiple species of bacteria from a wound specimen is common in many studies [97]. This notion is
further supported by previous microbiome studies of the wound that revealed the presence of complex
interspecies interactions that can affect the healing process [98]. Pyrosequencing techniques showed a
large microbial diversity within wounds with more than 100 different bacterial genera belonging to
strict and facultative anaerobes generally unidentified by standard culturing techniques [21,99]. Our
observations provide novel information about the complexity of the ulcer microenvironment, which
appears to be invariably characterized by a strong biofilm production sustained by either non-MDRO
or MDRO strains, often supported by polymicrobial associations. This notion reinforces the concept
that bacterial species may act synergistically during the colonization of ulcers and further suggests
that the formation of a structured biofilm matrix is key in the “critical colonization” process and in
the promotion of chronicity. Indeed, biofilm production may provide key virulence properties to
colonizing bacteria including protection from the host immune response as well as by making the
microorganism more generically tolerant to a broad range of antibiotics, as compared to non-biofilm
producers. Furthermore, such biofilm-endowed mixed colonization might also promote the acquisition
of novel drug resistance properties favoring the exchange of diffusible genetic materials.
Knowledge of the characteristics and properties of such polymicrobial colonization provides
novel interpretation to the “critical colonization” concept, which may help in supporting a more
thoughtful approach at the clinical management of chronic ulcers and future therapeutic strategies
aimed at attacking the biofilm matrix.
4. Materials and Methods
The Central Ethics Committee I.R.C.C.S. Lazio, section of the Istituti Fisioterapici Ospitalieri in
Rome, approved this study (Prot. CE/1016/15—15 December 2015, trials registry N. 730/15).
4.1. Inclusion Criteria
The study included only those patients with colonized skin ulcers according to specified
guidelines [12,100–104]. Briefly, an ulcer was classified as chronic when it persisted since at least
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3 months [104]. Exclusion criteria were the presence of fungi in a polymicrobial infection and a
pre-existing systemic antimicrobial treatment and/or local antiseptic therapy within 2 weeks prior to
ulcer sampling.
4.2. Sample Collection
Sample collection was performed from a total of 87 patients with colonized skin ulcers attending
the Istituti Fisioterapici Ospitalieri (IFO), which include the San Gallicano Dermatologic Institute and
the “Regina Elena” National Cancer Institute, in Rome, Italy, from January 2013 to December 2015.
Sample collection was performed by commercially available sterile swabs (COPAN swabs, Brescia,
Italy), according to existing departmental guidelines. Only one swab per patient was collected after
careful wound cleaning and debridement in order to prevent surface contamination.
The samples were processed within two hours after collection for culture analysis and
biofilm assessment.
4.3. Bacterial Identification
Swabs were immediately inoculated on Columbia CNA Agar with 5% Sheep Blood (bioMérieux,
Bagno a Ripoli, Italia), MacConkey Agar (bioMérieux, Bagno a Ripoli, Italia), Sabouraud Agar with
gentamicin (bioMérieux, Bagno a Ripoli, Italia) and S. aureus ID Agar (SAID; bioMérieux, Bagno a
Ripoli, Italia) for the isolation and cultivation of Gram-positive and Gram-negative bacteria. Inoculated
plates were incubated at 37 ◦C aerobically for 24 to 48 h. The chromogenic media SAID Agar was used
for the initial identification of S. aureus. Additional confirmation tests for MRSA, such as agglutination
tests for Penicillin-Binding Protein (PBP2, Oxoid, Basingstoke, UK) and cefoxitin screening, were
performed. The automatic VITEK® 2 (bioMérieux, Bagno a Ripoli, Italia) was used for the identification
of the bacterial species and for the definition of the specific antimicrobial susceptibility tests [105],
according to The European Committee on Antimicrobial Susceptibility Testing (EUCAST Clinical
Breakpoint Table v 7.1). In case of vancomycin resistant S. aureus strains, identified by VITEK® 2
(bioMérieux, Bagno a Ripoli, Italia), the antimicrobial susceptibility was further verified by the minimal
inhibitory concentration methods (Thermo Scientific, Basingstoke, UK).
MDROs were defined as MRSA, ESBL-producing K. pneumoniae and E. coli, P. aeruginosa
MDR and A. baumannii MDR, according to the Healthcare Infection Control Practices Advisory
Committee (HICPAC) guidelines [106] and the local infection control committee. Phenotypic
detection of ESBL producers was further defined using disk approximation tests (Thermo Scientific,
Basingstoke, UK) as previously described [107,108]. P. aeruginosa was defined MDR when resistant
to at least one antimicrobial agent of at least three categories of antimicrobial agents selected from
the following: aminoglycosides (gentamicin, tobramycin, amikacin, netilmicin), antipseudomonal
carbapenem (imipenem, meropenem, doripenem), antipseudomonal cephalosporin (ceftazidime,
cefepime), antipseudomonal fluoroquinolones (ciprofloxacin, levofloxacin), antipseudomonal
penicillins + β-lactamase inhibitors (piperacillin-tazobactam, ticarcillin-clavulanic acid), monobactams
(aztreonam), phosphonic acids (fosfomycin) and polymyxins (colistin, polymyxin B). A. baumannii
was defined as MDR when resistant to at least one antimicrobial agent of at least three
categories of antimicrobial agents selected from the following: aminoglycosides (gentamicin,
amikacin, netilmicin), carbapenem (imipenem, meropenem), cephalosporin (cefotaxime, ceftazidime,
cefepime), fluoroquinolones (ciprofloxacin, levofloxacin), and penicillins + β-lactamase inhibitors
(ampicillin-sulbactam, piperacillin-tazobactam, ticarcillin-clavulanic acid). The MDRO were frozen
and stored at −80 ◦C.
4.4. Evaluation of Biofilm Production
Biofilm production was evaluated by the clinical BioFilm Ring Test (cBRT) [35]. Briefly, overnight
culture of bacteria grown on specific agar plate was used to inoculate, 2 mL of 0.45% saline solution
(AirLife, Carefusion, San Diego, CA, USA) to the equivalent of 1.0 ± 0.3 McFarland turbidity standard.
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The bacterial suspension was used to inoculate a 96-well polystyrene plate with 200 µL/well. The test
was performed using toner solution (TON004) (Biofilm Control, Saint Beauzire, France) containing
magnetic beads 1% (v/v) mixed in Brain Heart Infusion medium (BHI, Difco, Detroit, MI, USA).
Sample dilutions (10-fold serial dilutions), were done in a volume of 200 µL BHI/TON mix.
One or more laboratory strains were included in each plate as standard reference and quality
control. A well containing the BHI/TON mix without microbial cells was used as negative control in
each experiment.
After five hours of incubation at 37 ◦C without shaking (static culture), wells were covered
with a few drops of contrast liquid (inert opaque oil used) placed for 1 min on the block carrying
96 mini-magnets (Block test) and scanned with a specifically designed plate reader (Pack BIOFILM,
Biofilm Control, Saint Beauzire, France). The adhesion strength of each strain was expressed as BioFilm
Index (BFI) Each microbial culture was analyzed in duplicate and experiments were repeated at 3 times
for each strain.
4.5. Statistic Analysis
Statistical analysis was performed using the chi-square test for linear trend and adjusted for
multiple comparisons when appropriate. Data analysis was calculated using one-way ANOVA.
p-values of 0.05 or less were considered statistical significant. All statistical analyses were performed
using IBM SPSS v.21 statistics software (IBM, Chicago, IL, USA).
5. Conclusions
Epidemiology of MDROs is extremely complex and multifactorial, varying temporally and
geographically, and further depending on patients’ characteristics. In this study on patients with
chronic skin ulcers, MDRO frequencies accounted for the 31.8% of the total isolates. Our results
showed a high prevalence of Gram-negative bacteria (60.8%) and, among this group, P. aeruginosa
was the most frequent pathogen isolated. Nevertheless, considering the individual bacterial species,
S. aureus was found to be the most common pathogen with linezolid and tigecycline being the most
effective antimicrobials. Globally, carbapenem and colistin were the most effective antimicrobial agents
against all Gram-negative MDRO.
Up to 80.5% of the microbial strains analyzed were able to produce biofilm. Notably, non-biofilm
producers or poor producers were always found to be in association with biofilm producers,
suggesting that bacterial species growing in polymicrobial colonization may act synergistically,
forming biofilm-embedded communities mutually interacting in the promotion of wound chronicity.
These results further point to biofilm formation as a key determinant of pathogenicity, capable of
promoting a successful, persistent colonization of the wound site, independently from the acquisition
of multidrug resistance.
Acknowledgments: This work was supported by the L’Associazione Nazionale Contro le Infezioni
Ospedaliere (L’ANCIO).
Author Contributions: Enea Gino Di Domenico, Ilaria Farulla, Grazia Prignano, Maria Teresa Gallo
and Fabrizio Ensoli participated in the conception and design of the study; Enea Gino Di Domenico,
Ilaria Farulla and Ilaria Cavallo performed the experiments and organized the work activities within the team;
Isabella Sperduti performed statistical analysis; Enea Gino Di Domenico, Ilaria Farulla, Matteo Vespaziani,
Ilaria Cavallo, Martina Pontone, Valentina Bordignon, Laura Cilli, Alessandra De Santis Fabiola Di Salvo,
Fulvia Pimpinelli, Ilaria Lesnoni La Parola and Luigi Toma contributed to patient enrollment and data collection;
Enea Gino Di Domenico, Luigi Toma, Fulvia Pimpinelli, Ilaria Lesnoni La Parola and Fabrizio Ensoli drafted the
manuscript. All authors read and approved the final version of the manuscript.
Conflicts of Interest: The authors declare that there is no conflict of interest with any financial organization
regarding the material discussed in the manuscript.
Int. J. Mol. Sci. 2017, 18, 1077 14 of 19
References
1. Siegel, J.D.; Rhinehart, E.; Jackson, M.; Chiarello, L. Management of multidrug-resistant organisms in
healthcare settings, 2006. Am. J. Infect. Control 2007, 35, 165–193. [CrossRef] [PubMed]
2. Cosgrove, S.E. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of
hospital stay, and health care costs. Clin. Infect. Dis. 2006, 42, 82–89. [CrossRef] [PubMed]
3. Lautenbach, E.; Patel, J.B.; Bilker, W.B.; Edelstein, P.H.; Fishman, N.O. Extended-spectrum
β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Risk factors for infection and impact
of resistance on outcomes. Clin. Infect. Dis. 2001, 32, 1162–1171. [CrossRef] [PubMed]
4. Richard, J.L.; Sotto, A.; Jourdan, N.; Combescure, C.; Vannereau, D.; Rodier, M.; Lavigne, J.P. Risk factors
and healing impact of multidrug-resistant bacteria in diabetic foot ulcers. Diabete Metab. 2008, 34, 363–369.
[CrossRef] [PubMed]
5. Trivedi, U.; Parameswaran, S.; Armstrong, A.; Burgueno-Vega, D.; Griswold, J.; Dissanaike, S.;
Rumbaugh, K.P. Prevalence of multiple antibiotic resistant infections in diabetic versus nondiabetic wounds.
J. Pathog. 2014, 2014, 173053. [CrossRef] [PubMed]
6. Gottrup, F. Optimizing wound treatment through health care structuring and professional education.
Wound Repair Regen. 2004, 12, 129–133. [CrossRef] [PubMed]
7. Sen, C.K.; Gordillo, G.M.; Roy, S.; Kirsner, R.; Lambert, L.; Hunt, T.K.; Gottrup, F.; Gurtner, G.C.;
Longaker, M.T. Human skin wounds: A major and snowballing threat to public health and the economy.
Wound Repair Regen. 2009, 17, 763–771. [CrossRef] [PubMed]
8. Hartemann-Heurtier, A.; Robert, J.; Jacqueminet, S.; Van Ha, G.; Golmard, J.L.; Jarlier, V.; Grimaldi, A.
Diabetic foot ulcer and multidrug-resistant organisms: Risk factors and impact. Diabet. Med. 2004, 21,
710–715. [CrossRef] [PubMed]
9. Jenkins, T.C.; Sabel, A.L.; Sarcone, E.E.; Price, C.S.; Mehler, P.S.; Burman, W.J. Skin and soft-tissue infections
requiring hospitalization at an academic medical center: Opportunities for antimicrobial stewardship.
Clin. Infect. Dis. 2010, 51, 895–903. [CrossRef] [PubMed]
10. Siddiqui, A.R.; Bernstein, J.M. Chronic wound infection: Facts and controversies. Clin. Dermatol. 2010, 28,
519–526. [CrossRef] [PubMed]
11. Egbe, C.A.; Omoregie, R.; Igbarumah, I.O.; Onemu, S. Microbiology of wound infections among patients of a
tertiary hospital in Benin City, Nigeria. J. Res. Health Sci. 2011, 11, 109–113. [PubMed]
12. Bowler, P.G.; Duerden, B.I.; Armstrong, D.G. Wound microbiology and associated approaches to wound
management. Clin. Microbiol. Rev. 2001, 14, 244–269. [CrossRef] [PubMed]
13. Ramakant, P.; Verma, A.K.; Misra, R.; Prasad, K.N.; Chand, G.; Mishra, A.; Agarwal, G.; Agarwal, A.;
Mishra, S.K. Changing microbiological profile of pathogenic bacteria in diabetic foot infections: Time for a
rethink on which empirical therapy to choose? Diabetologia 2011, 54, 58–64. [CrossRef] [PubMed]
14. Lipsky, B.A.; Berendt, A.R.; Cornia, P.B.; Pile, J.C.; Peters, E.J.; Armstrong, D.G.; Deery, H.G.; Embil, J.M.;
Joseph, W.S.; Karchmer, A.W.; et al. 2012 Infectious diseases society of America clinical practice guideline
for the diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. 2012, 54, e132–e173. [CrossRef]
[PubMed]
15. Seth, A.K.; Geringer, M.R.; Hong, S.J.; Leung, K.P.; Mustoe, T.A.; Galiano, R.D. In vivo modelling of
biofilm-infected wounds: A review. J. Surg. Res. 2012, 178, 330–338. [CrossRef] [PubMed]
16. Percival, S.L.; McCarty, S.M.; Lipsky, B. Biofilms and wounds: An overview of the evidence. Adv. Wound
Care (New Rochelle) 2015, 4, 373–381. [CrossRef] [PubMed]
17. Di Domenico, E.G. Microbial biofilms in dermatology: A matter of skin. Esperienze Dermatologiche 2015, 17,
163–166.
18. Kingsley, A. A proactive approach to wound infection. Nurs. Stand. 2001, 15, 50–58. [CrossRef] [PubMed]
19. Edwards, R.; Harding, K.G. Bacteria and wound healing. Curr. Opin. Infect. Dis. 2004, 17, 91–96. [CrossRef]
[PubMed]
20. White, R.J.; Cutting, K.F. Critical colonisation—The concept under scrutiny. Ostomy Wound Manag. 2006, 52,
50–56.
21. Zhao, G.; Usui, M.L.; Lippman, S.I.; James, G.A.; Stewart, P.S.; Fleckman, P.; Olerud, J.E. Biofilms and
inflammation in chronic wounds. Adv. Wound Care (New Rochelle) 2013, 2, 389–399. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1077 15 of 19
22. James, G.A.; Swogger, E.; Wolcott, R.; Pulcini, E.D.; Secor, P.; Sestrich, J.; Costerton, J.W.; Stewart, P.S. Biofilms
in chronic wounds. Wound Repair Regen. 2008, 16, 37–44. [CrossRef] [PubMed]
23. Hengzhuang, W.; Wu, H.; Ciofu, O.; Song, Z.; Høiby, N. In vivo pharmacokinetics/pharmacodynamics of
colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob. Agents Chemother. 2012, 56,
2683–2690. [CrossRef] [PubMed]
24. Beloin, C.; Ghigo, J.M. Finding gene-expression patterns in bacterial biofilms. Trends Microbiol. 2005, 13,
16–19. [CrossRef] [PubMed]
25. Percival, S.L.; Suleman, L.; Vuotto, C.; Donelli, G. Healthcare-associated infections, medical devices and
biofilms: Risk, tolerance and control. J. Med. Microbiol. 2015, 64, 323–334. [CrossRef] [PubMed]
26. Reiter, K.C.; Da Silva Paim, T.G.; De Oliveira, C.F.; D’Azevedo, P.A. High biofilm production by invasive
multiresistant staphylococci. APMIS 2011, 119, 776–781. [CrossRef] [PubMed]
27. Kwon, A.S.; Park, G.C.; Ryu, S.Y.; Lim, D.H.; Lim, D.Y.; Choi, C.H.; Park, Y.; Lim, Y. Higher biofilm formation
in multidrug-resistant clinical isolates of Staphylococcus aureus. Int. J. Antimicrob. Agents 2008, 32, 68–72.
[CrossRef] [PubMed]
28. Rao, R.S.; Karthika, R.U.; Singh, S.P.; Shashikala, P.; Kanungo, R.; Jayachandran, S.; Prashanth, K.
Correlation between biofilm production and multiple drug resistance in imipenem resistant clinical isolates
of Acinetobacter baumannii. Indian J. Med. Microbiol. 2008, 26, 333–337. [PubMed]
29. Sanchez, C.J., Jr.; Mende, K.; Beckius, M.L.; Akers, K.S.; Romano, D.R.; Wenke, J.C.; Murray, C.K. Biofilm
formation by clinical isolates and the implications in chronic infections. BMC Infect. Dis. 2013, 13, 47.
[CrossRef] [PubMed]
30. Kaeberlein, T.; Lewis, K.; Epstein, S.S. Isolating “uncultivable” microorganisms in pure culture in a simulated
natural environment. Science 2002, 296, 1127–1129. [CrossRef] [PubMed]
31. Bjarnsholt, T.; Kirketerp-Møller, K.; Jensen, P.Ø.; Madsen, K.G.; Phipps, R.; Krogfelt, K.; Høiby, N.; Givskov, M.
Why chronic wounds will not heal: A novel hypothesis. Wound Repair Regen. 2008, 16, 2–10. [CrossRef]
[PubMed]
32. Macià, M.D.; Rojo-Molinero, E.; Oliver, A. Antimicrobial susceptibility testing in biofilm—Growing bacteria.
Clin. Microbiol. Infect. 2014, 20, 981–990. [CrossRef] [PubMed]
33. Cooper, R.A.; Bjarnsholt, T.; Alhede, M. Biofilms in wounds: A review of present knowledge. J. Wound Care
2014, 23, 570–582. [CrossRef] [PubMed]
34. Eum, S.; Bergsbaken, R.L.; Harvey, C.L.; Warren, J.B.; Rotschafer, J.C. Discrepancy in vancomycin AUC/MIC
ratio targeted attainment based upon the susceptibility testing in Staphylococcus aureus. Antibiotics 2016, 5, 34.
[CrossRef] [PubMed]
35. Di Domenico, E.G.; Toma, L.; Provot, C.; Ascenzioni, F.; Sperduti, I.; Prignano, G.; Gallo, M.T.; Pimpinelli, F.;
Bordignon, V.; Bernardi, T.; et al. Development of an in vitro assay, based on the Biofilm Ring Test®, for
rapid profiling of biofilm—Growing bacteria. Front. Microbiol. 2016, 7, 1429. [CrossRef] [PubMed]
36. Abdulrazak, A.; Bitar, Z.I.; Al-Shamali, A.A.; Mobasher, L.A. Bacteriological study of diabetic foot infections.
J. Diabetes Complicat. 2005, 19, 138–141. [CrossRef] [PubMed]
37. Körber, A.; Schmid, E.N.; Buer, J.; Klode, J.; Schadendorf, D.; Dissemond, J. Bacterial colonization of chronic
leg ulcers: Current results compared with data 5 years ago in a specialized dermatology department. J. Eur.
Acad. Dermatol. Venereol. 2010, 24, 1017–1025. [CrossRef] [PubMed]
38. Oien, R.F.; Akesson, N. Bacterial cultures, rapid strep test, and antibiotic treatment in infected hard-to-heal
ulcers in primary care. Scand. J. Prim. Health Care 2012, 30, 254–258. [CrossRef] [PubMed]
39. Shanmugam, P.; Jeya, M.; Susan, S.L. The bacteriology of diabetic foot ulcers, with a special reference to
multidrug resistant strains. J. Clin. Diagn. Res. 2013, 7, 441–445. [CrossRef] [PubMed]
40. Hoeger, P.H.; Lenz, W.; Boutonnier, A.; Fournier, J.M. Staphylococcal skin colonization in children with atopic
dermatitis: Prevalence, persistence, and transmission of toxigenic and nontoxigenic strains. J. Infect. Dis.
1992, 165, 1064–1068. [CrossRef] [PubMed]
41. Kac, G.; Buu-Hoï, A.; Hérisson, E.; Biancardini, P.; Debure, C. Methicillin-resistent Staphylococcus aureus.
Nosocomial acquisition and carrier state in a wound care center. Arch. Dermatol. 2000, 136, 735–739.
[CrossRef] [PubMed]
42. Gjødsbøl, K.; Skindersoe, M.E.; Skov, R.L.; Krogfelt, K.A. Cross-Contamination: Comparison of nasal and
chronic leg ulcer Staphylococcus aureus Strains isolated from the same patient. Open Microbiol. J. 2013, 7, 6–8.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1077 16 of 19
43. Stanaway, S.; Johnson, D.; Moulik, P.; Gill, G. Methicillin-Resistant Staphylococcus aureus (MRSA) isolation
from diabetic foot ulcers correlates with nasal MRSA carriage. Diabetes Res. Clin. Pract. 2007, 75, 47–50.
[CrossRef] [PubMed]
44. Demling, R.H.; Waterhouse, B. The increasing problem of wound bacterial burden and infection in acute and
chronic soft-tissue wounds caused by methicillin-resistant Staphylococcus aureus. J. Burns Wounds 2007, 7, e8.
[PubMed]
45. Jockenhöfer, F.; Gollnick, H.; Herberger, K.; Isbary, G.; Renner, R.; Stücker, M.; Valesky, E.; Wollina, U.;
Weichenthal, M.; Karrer, S.; et al. Bacteriological pathogen spectrum of chronic leg ulcers: Results of a
multicenter trial in dermatologic wound care centers differentiated by regions. J. Dtsch. Dermatol. Ges. 2013,
11, 1057–1063. [CrossRef] [PubMed]
46. Moore, K.; Hall, V.; Paull, A.; Morris, T.; Brown, S.; McCulloch, D.; Richardson, M.C.; Harding, K.G. Surface
bacteriology of venous leg ulcers and healing outcome. J. Clin. Pathol. 2010, 63, 830–834. [CrossRef]
[PubMed]
47. Fazli, M.; Bjarnsholt, T.; Kirketerp-Møller, K.; Jørgensen, B.; Andersen, A.S.; Krogfelt, K.A.; Givskov, M.;
Tolker-Nielsen, T. Nonrandom distribution of Pseudomonas aeruginosa and Staphylococcus aureus in chronic
wounds. J. Clin. Microbiol. 2009, 47, 4084–4089. [CrossRef] [PubMed]
48. Peters, B.M.; Jabra-Rizk, M.A.; O’May, G.A.; Costerton, J.W.; Shirtliff, M.E. Polymicrobial interactions: Impact
on pathogenesis and human disease. Clin. Microbiol. Rev. 2012, 25, 193–213. [CrossRef] [PubMed]
49. Kirketerp-Møller, K.; Jensen, P.Ø.; Fazli, M.; Madsen, K.G.; Pedersen, J.; Moser, C.; Tolker-Nielsen, T.;
Høiby, N.; Givskov, M.; Bjarnsholt, T. Distribution, organization, and ecology of bacteria in chronic wounds.
J. Clin. Microbiol. 2008, 46, 2717–2722.
50. Wang, J.T.; Chen, P.C.; Chang, S.C.; Shiau, Y.R.; Wang, H.Y.; Lai, J.F.; Huang, I.W.; Tan, M.C.; Lauderdale, T.L.
Antimicrobial susceptibilities of Proteus mirabilis: A longitudinal nationwide study from the Taiwan
surveillance of antimicrobial resistance (TSAR) program. BMC Infect. Dis. 2014, 14, 486. [CrossRef]
[PubMed]
51. Park, Y.J.; Lee, S.; Kim, Y.R.; Oh, E.J.; Woo, G.J.; Lee, K. Occurence of extended-spectrum β-lactamases and
plasmid-mediated AmpC β-lactamases among Korean isolates of Proteus mirabilis. J. Antimicrob. Chemother.
2006, 57, 156–158. [CrossRef] [PubMed]
52. D’Andrea, M.M.; Nucleo, E.; Luzzaro, F.; Giani, T.; Migliavacca, R.; Vailati, F.; Kroumova, V.; Pagani, L.;
Rossolini, G.M. CMY-16, a novel acquired AmpC-type β-lactamase of the CMY/LAT lineage in multifocal
monophyletic isolates of Proteus mirabilis from Northern Italy. Antimicrob. Agents Chemother. 2006, 50,
618–624. [CrossRef] [PubMed]
53. Aragón, L.M.; Mirelis, B.; Miró, E.; Mata, C.; Gómez, L.; Rivera, A.; Coll, P.; Navarro, F. Increase in
β-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and
inhibitor-resistant TEM-type β-lactamases. J. Antimicrob. Chemother. 2008, 61, 1029–1032. [CrossRef]
[PubMed]
54. Power, P.; Galleni, M.; Ayala, J.A.; Gutkind, G. Biochemical and molecular characterization of three new
variants of AmpC β-lactamases from Morganella morganii. Antimicrob. Agents Chemother. 2006, 50, 962–967.
[CrossRef] [PubMed]
55. Attinger, C.; Wolcott, R. Clinically addressing biofilm in chronic wounds. Adv. Wound Care (New Rochelle)
2012, 1, 127–132. [CrossRef] [PubMed]
56. Fazli, M.; Bjarnsholt, T.; Kirketerp-Møller, K.; Jørgensen, A.; Andersen, C.B.; Givskov, M.; Tolker-Nielsen, T.
Quantitative analysis of the cellular inflammatory response against biofilm bacteria in chronic wounds.
Wound Repair Regen. 2011, 19, 387–391. [CrossRef] [PubMed]
57. Ghigo, J.M. Natural conjugative plasmids induce bacterial biofilm development. Nature 2001, 412, 442–445.
[CrossRef] [PubMed]
58. Madsen, J.S.; Burmølle, M.; Hansen, L.H.; Sørensen, S.J. The interconnection between biofilm formation and
horizontal gene transfer. FEMS Immunol. Med. Microbiol. 2012, 65, 183–195. [CrossRef] [PubMed]
59. Lebeaux, D.; Ghigo, J.M.; Beloin, C. Biofilm-related infections: Bridging the gap between clinical management
and fundamental aspects of recalcitrance toward antibiotics. Microbiol. Mol. Biol. Rev. 2014, 78, 510–543.
[CrossRef] [PubMed]
60. Ehlers, L.J.; Bouwer, E.J. RP4 plasmid transfer among species of Pseudomonas in a biofilm reactor.
Water Sci. Technol. 1999, 39, 163–171. [CrossRef]
Int. J. Mol. Sci. 2017, 18, 1077 17 of 19
61. Stalder, T.; Top, E. Plasmid transfer in biofilms: A perspective on limitations and opportunities. NPJ Biofilms
Microbiomes 2016, 2, 16022. [CrossRef] [PubMed]
62. Driffield, K.; Miller, K.; Bostock, J.M.; O’Neill, A.J.; Chopra, I. Increased mutability of Pseudomonas
aeruginosa in biofilms. J. Antimicrob. Chemother. 2008, 61, 1053–1056. [CrossRef] [PubMed]
63. Allegrucci, M.; Sauer, K. Formation of Streptococcus pneumoniae non-phase variable colony variants is due
to increased mutation frequency present under biofilm growth conditions. J. Bacteriol. 2008, 190, 6330–6339.
[CrossRef] [PubMed]
64. Ryder, V.J.; Chopra, I.; O’Neill, A.J. Increased mutability of Staphylococci in biofilms as a consequence of
oxidative stress. PLoS ONE 2012, 7, e47695. [CrossRef] [PubMed]
65. Madsen, J.S.; Burmølle, M.; Sørensen, S.J. A spatiotemporal view of plasmid loss in biofilms and planktonic
cultures. Biotechnol. Bioeng. 2014, 110, 3071–3074. [CrossRef] [PubMed]
66. Patel, R. Biofilms and antimicrobial resistance. Clin. Orthop. Relat. Res. 2005, 437, 41–47. [CrossRef]
67. Wang, Q.; Sun, F.J.; Liu, Y.; Xiong, L.R.; Xie, L.L.; Xia, P.Y. Enhancement of biofilm formation by subinhibitory
concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis.
Antimicrob. Agents Chemother. 2010, 54, 2707–2711. [CrossRef] [PubMed]
68. Anderl, J.N.; Franklin, M.J.; Stewart, P.S. Role of antibiotic penetration limitation in Klebsiella pneumoniae
biofilm resistance to ampicillin and ciprofloxacin. Antimicrob. Agents Chemother. 2000, 44, 1818–1824.
[CrossRef] [PubMed]
69. Vrany, J.D.; Stewart, P.S.; Suci, P.A. Comparison of recalcitrance to ciprofloxacin and levofloxacin exhibited
by Pseudomonas aeruginosa bofilms displaying rapid-transport characteristics. Antimicrob. Agents Chemother.
1997, 41, 1352–1358. [PubMed]
70. Stone, G.; Wood, P.; Dixon, L.; Keyhan, M.; Matin, A. Tetracycline rapidly reaches all the constituent cells
of uropathogenic Escherichia coli biofilms. Antimicrob. Agents Chemother. 2002, 46, 2458–2461. [CrossRef]
[PubMed]
71. Zheng, Z.; Stewart, P.S. Penetration of rifampin through Staphylococcus epidermidis biofilms. Antimicrob. Agents
Chemother. 2002, 4, 900–903. [CrossRef]
72. Darouiche, R.O.; Dhir, A.; Miller, A.J.; Landon, G.C.; Raad, I.I.; Musher, D.M. Vancomycin penetration into
biofilm covering infected prostheses and effect on bacteria. J. Infect. Dis. 1994, 170, 720–723. [CrossRef]
[PubMed]
73. Del Pozo, J.L.; Patel, R. The challenge of treating biofilm-associated bacterial infections. Clin. Pharmacol. Ther.
2007, 82, 204–209. [CrossRef] [PubMed]
74. Stewart, P.S. Antimicrobial Tolerance in Biofilms. Microbiol. Spectr. 2015, 3. [CrossRef]
75. Smith, K.; Perez, A.; Ramage, G.; Lappin, D.; Gemmell, C.G.; Lang, S. Biofilm formation by Scottish clinical
isolates of Staphylococcus aureus. J. Med. Microbiol. 2008, 57, 1018–1023. [CrossRef] [PubMed]
76. Karauzum, H.; Ferry, T.; de Bentzmann, S.; Lina, G.; Bes, M.; Vandenesch, F.; Schmaler, M.; Berger-Bächi, B.;
Etienne, J.; Landmann, R. Comparison of Adhesion and Virulence of Two Predominant Hospital-Acquired
Methi-cillin-Resistant Staphylococcus aureus Clones and Clonal Methicillin-Susceptible Staphylococcus aureus
Isolates. Infect. Immun. 2008, 76, 5133–5138. [CrossRef] [PubMed]
77. Doulgeraki, A.I.; Di Ciccio, P.; Ianieri, A.; Nychas, G.E. Methicillin-resistant food-related Staphylococcus aureus:
A review of current knowledge and biofilm formation for future studies and applications. Res. Microbiol.
2017, 168, 1–15. [CrossRef] [PubMed]
78. Mirzaee, M.; Najar-Peerayeh, S.; Behmanesh, M.; Forouzandeh, M. Relationship between adhesin genes and
biofilm formation in vancomycin-intermediate Staphylococcus aureus clinical isolates. Curr. Microbial. 2015,
70, 665–670. [CrossRef] [PubMed]
79. Pozzi, C.; Waters, E.M.; Rudkin, J.K.; Schaeffer, C.R.; Lohan, A.J.; Tong, P.; Loftus, B.J.; Pier, G.B.; Fey, P.D.;
Massey, R.C.; et al. Methicillin resistance alters the biofilm phenotype and attenuates virulence in
Staphylococcus aureus device-associated infections. PLoS Pathog. 2012, 8, e1002626. [CrossRef] [PubMed]
80. McCarthy, H.; Rudkin, J.K.; Black, N.S.; Gallagher, L.; O’Neill, E.; O’Gara, J.P. Methicillin resistance and the
biofilm phenotype in Staphylococcus aureus. Front. Cell. Infect. Microbiol. 2015, 5, 1. [CrossRef] [PubMed]
81. Rudkin, J.K.; Laabei, M.; Edwards, A.M.; Joo, H.; Otto, M.; Lennon, K.L.; O’Gara, J.P.; Waterfield, N.R.;
Massey, R.C. Oxacillin alters the toxin expression profile of community-associated methicillin-resistant
Staphylococcus aureus. Antimicrob. Agents Chemother. 2014, 58, 1100–1107. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 1077 18 of 19
82. Moradali, M.F.; Ghods, S.; Rehm, B.H.A. Pseudomonas aeruginosa lifestyle: A paradigm for adaptation,
survival, and persistence. Front. Cell. Infect. Microbiol. 2017, 7, 39. [CrossRef] [PubMed]
83. Ghanbarzadeh Corehtash, Z.; Khorshidi, A.; Firoozeh, F.; Akbari, H.; Mahmoudi Aznaveh, A.
Biofilm formation and virulence factors among Pseudomonas aeruginosa isolated from burn patients.
Jundishapur J. Microbiol. 2015, 8, e22345. [CrossRef] [PubMed]
84. Abidi, S.H.; Sherwani, S.K.; Siddiqui, T.R.; Bashir, A.; Kazmi, S.U. Drug resistance profile and biofilm forming
potential of Pseudomonas aeruginosa isolated from contact lenses in Karachi-Pakistan. BMC Ophthalmol. 2013,
13, 57. [CrossRef] [PubMed]
85. Pastar, I.; Nusbaum, A.G.; Gil, J.; Patel, S.B.; Chen, J.; Valdes, J.; Stojadinovic, O.; Plano, L.R.; Tomic-Canic, M.;
Davis, S.C. Interactions of methicillin resistant Staphylococcus aureus USA300 and Pseudomonas aeruginosa in
polymicrobial wound infection. PLoS ONE 2013, 8, e56846. [CrossRef] [PubMed]
86. Hendricks, K.J.; Burd, T.A.; Anglen, J.O.; Simpson, A.W.; Christensen, G.D.; Gainor, BJ. Synergy between
Staphylococcus aureus and Pseudomonas aeruginosa in a rat model of complex orthopaedic wounds. J. Bone Jt.
Surg. Am. 2001, 83, 855–861. [CrossRef]
87. DeLeon, S.; Clinton, A.; Fowler, H.; Everett, J.; Horswill, A.R.; Rumbaugh, K.P. Synergistic interactions
of Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro wound model. Infect. Immun. 2014, 82,
4718–4728. [CrossRef] [PubMed]
88. Rosenbluth, D.B.; Wilson, K.; Ferkol, T.; Schuster, D.P. Lung function decline in cystic fibrosis patients and
timing for lung transplantation referral. Chest 2004, 126, 412–419. [CrossRef] [PubMed]
89. Fournier, P.E.; Richet, H. The epidemiology and control of Acinetobacter baumannii in health care facilities.
Clin. Infect. Dis. 2006, 42, 692–699. [CrossRef] [PubMed]
90. Rodriguez-Bano, J.; Marti, S.; Soto, S.; Fernandez-Cuenca, F.; Cisneros, J.M.; Pachon, J.; Pascual, A.;
Martínez-Martínez, L.; McQueary, C.; Actis, L.A.; et al. Biofilm formation in Acinetobacter baumannii:
Associated features and clinical implications. Clin. Microbiol. Infect. 2008, 14, 276–278. [CrossRef] [PubMed]
91. Marti, S.; Rodriguez-Bano, J.; Catel-Ferreira, M.; Jouenne, T.; Vila, J.; Seifert, H.; Dé, E. Biofilm formation
at the solid-liquid and air-liquid interfaces by Acinetobacter species. BMC Res. Notes 2011, 4, 5. [CrossRef]
[PubMed]
92. Hu, Y.; He, L.; Tao, X.; Meng, F.; Zhang, J. Biofilm may not be necessary for the epidemic spread of
Acinetobacter baumannii. Sci. Rep. 2016, 6, 32066. [CrossRef] [PubMed]
93. Perez, L.R. Acinetobacter baumannii displays inverse relationship between meropenem resistance and
biofilm production. J. Chemother. 2015, 27, 13–16. [CrossRef] [PubMed]
94. Qi, L.; Li, H.; Zhang, C.; Liang, B.; Li, J.; Wang, L.; Du, X.; Liu, X.; Qiu, S.; Song, H. Relationship
between antibiotic resistance, biofilm formation, and biofilm-specific resistance in Acinetobacter baumannii.
Front. Microbiol. 2016, 7, 483. [CrossRef] [PubMed]
95. Yang, D.; Zhang, Z. Biofilm-forming Klebsiella pneumoniae strains have greater likelihood of producing
extended-spectrum β-lactamases. J. Hosp. Infect. 2008, 68, 369–371. [CrossRef] [PubMed]
96. Vuotto, C.; Longo, F.; Balice, M.P.; Donelli, G.; Varaldo, P.E. Antibiotic resistance related to biofilm formation
in Klebsiella pneumoniae. Pathogens 2014, 3, 743–758. [CrossRef] [PubMed]
97. Lipsky, B.A.; Pecoraro, R.E.; Wheat, L.J. The diabetic foot: Soft tissue and bone infection. Infect. Dis. N. Am.
1990, 4, 409–432.
98. Dowd, S.E.; Wolcott, R.D.; Sun, Y.; McKeehan, T.; Smith, E.; Rhoads, D. Polymicrobial nature of chronic
diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing
(bTEFAP). PLoS ONE 2008, 3, e3326. [CrossRef] [PubMed]
99. Dowd, S.E.; Sun, Y.; Secor, P.R.; Rhoads, D.D.; Wolcott, B.M.; James, G.A.; Wolcott, R.D. Survey of
bacterial diversity in chronic wounds using pyrosequencing, DGGE, and full ribosome shotgun sequencing.
BMC Microbiol. 2008, 8, 43. [CrossRef] [PubMed]
100. Browne, A.C.; Vearncombe, M.; Sibbald, R.G. High bacterial load in asymptomatic diabetic patients with
neurotrophic ulcers retards wound healing after application of Dermagraft. Ostomy Wound Manag. 2001, 47,
44–49.
101. Ovington, L. Bacterial toxins and wound healing. Ostomy Wound Manag. 2003, 49, 8–12.
102. Cutting, K.F.; White, R.J. Criteria for identifying wound infection-revisited. Ostomy Wound Manag. 2005, 51,
28–34.
Int. J. Mol. Sci. 2017, 18, 1077 19 of 19
103. White, R.; Cutting, K.F.; Kingsley, A. Critical colonisation: Clinical reality or myth? Wounds UK 2005, 1,
94–95.
104. Dissemond, J. When is a wound chronic? Hautarzt 2006, 57, 55. [CrossRef] [PubMed]
105. Di Domenico, E.G.; Toma, L.; Prignano, G.; Pelagalli, L.; Police, A.; Cavallotti, C.; Torelli, R.; Sanguinetti, M.;
Ensoli, F. Misidentification of Streptococcus uberis as a human pathogen: A casa report and literature review.
Int. J. Infect. Dis. 2015, 33, 79–81. [CrossRef] [PubMed]
106. Healthcare-Associated Infections. Available online: http://www.cdc.gov/ncidod/dhqp/pdf/ar/
mdroGuideline2006.pdf (accessed on 15 November 2016).
107. De Gheldre, Y.; Avesani, V.; Berhin, C.; Delmée, M.; Glupczynski, Y. Evaluation of Oxoid combination discs
for detection of extended-spectrum β-lactamases. J. Antimicrob. Chemother. 2003, 52, 591–597. [CrossRef]
[PubMed]
108. Moremi, N.; Mushi, M.F.; Fidelis, M.; Chalya, P.; Mirambo, M.; Mshana, S.E. Predominance of multi-resistant
gram-negative bacteria colonizing chronic lower limb ulcers (CLLUs) at Bugando Medical Center.
BMC Res. Notes 2014, 7, 211. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
